Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 24, 2012. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 425,000 Ordinary shares of 25 pence each.
- Purchase Date: February 24, 2012.
- Price Range: Highest price paid was 1,422.0 pence per share; lowest price paid was 1,405.0 pence per share.
- Treasury Holdings (Settled): 505,817,927 shares (9.10% of total issued share capital).
- Treasury Holdings (Including Unsettled): 507,207,927 shares (10.04% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,049,687,020 shares.
Material Changes
The filing reports an incremental increase in the Company's treasury share holdings following the purchase of 425,000 shares. No other material changes to operations or financial position are disclosed in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure regarding share buybacks under the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (505,817,927 settled) against the Company's latest annual report.
- Confirm the percentage of total voting rights held in Treasury (10.04% including unsettled shares) for disclosure threshold calculations.
- Check the total issued share capital excluding treasury shares (5,049,687,020) for accurate ownership percentage calculations.
- Note that this filing does not contain operational or financial performance data; refer to Form 20-F for comprehensive financial metrics.